Tango Therapeutics (NASDAQ:TNGX) Insider Sells $617,490.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $22.87, for a total transaction of $617,490.00. Following the completion of the sale, the insider directly owned 115,743 shares of the company’s stock, valued at $2,647,042.41. The trade was a 18.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Adam Crystal also recently made the following trade(s):

• On Friday, May 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.23, for a total transaction of $573,210.00.
• On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $961,500.00.
• On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total transaction of $572,400.00.
• On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $20.11, for a total transaction of $241,320.00.
• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $303,765.00.

Tango Therapeutics Stock Performance

Shares of NASDAQ TNGX opened at $20.22 on Friday. The company’s fifty day moving average price is $22.43 and its 200 day moving average price is $15.61. Tango Therapeutics, Inc. has a 1 year low of $3.58 and a 1 year high of $28.41. The company has a market capitalization of $2.92 billion, a PE ratio of -24.36 and a beta of 1.19.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%. On average, equities analysts expect that Tango Therapeutics, Inc. will post -1.29 EPS for the current year.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its stake in shares of Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock worth $97,000 after purchasing an additional 40,983 shares during the period. AQR Capital Management LLC acquired a new position in shares of Tango Therapeutics during the 1st quarter worth $195,000. Dynamic Technology Lab Private Ltd grew its stake in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares during the period. Woodline Partners LP grew its stake in shares of Tango Therapeutics by 28.3% during the 1st quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock worth $693,000 after purchasing an additional 111,791 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Tango Therapeutics by 270.6% during the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock worth $483,000 after purchasing an additional 257,668 shares during the period. 78.99% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TNGX has been the subject of a number of recent analyst reports. Piper Sandler cut shares of Tango Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $24.00 in a research report on Thursday, May 14th. Jefferies Financial Group cut shares of Tango Therapeutics from a “buy” rating to a “hold” rating and lifted their price target for the company from $18.00 to $27.00 in a research report on Thursday, May 14th. Weiss Ratings cut shares of Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. Wall Street Zen cut shares of Tango Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Stifel Nicolaus lifted their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tango Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.27.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.